Feed Top Reports Pricing

⌘K

16:50:45·49d

SECFiling

SEC Form 10-K filed by Lexicon Pharmaceuticals Inc.

LXRX· Lexicon Pharmaceuticals Inc.

Health Care

Original source

Companies

LXRX
Lexicon Pharmaceuticals Inc.
Health Care

Recent analyst ratings

Mar 5UpdateLeerink Partners$1.00
Jun 17UpdateH.C. Wainwright$10.00
Apr 30UpdateLeerink Partners$5.00
Mar 7UpdateJefferies$3.00
Aug 12UpdatePiper Sandler$10.00

Related

PR6d
Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting
PR30d
Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo
SEC38d
SEC Form DEFA14A filed by Lexicon Pharmaceuticals Inc.
SEC38d
SEC Form DEF 14A filed by Lexicon Pharmaceuticals Inc.
PR43d
Lexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for Diabetes
SEC49d
Lexicon Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
PR49d
Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates
PR51d
Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releases Analyst ratings Insider trading FDA SEC RSS feeds

Top lists

Trending By market cap Active companies Analyst upgrades Insider purchases FDA approvals SEC filings Sectors Market reports

Company

About Pricing Publish with us Contact

Legal

Terms of use Privacy policy Cookie policy

© 2026 quantisnow.com · Democratizing insights since 2022